Search
Categories


Posts Tagged ‘will’

Most Medicare Prescription Drug Plans Will Drop Coverage For Erectile Dysfunction Medications In 2007

Tuesday, June 1st, 2010

Most Medicare prescription drug plans in 2007 will not cover erectile dysfunction treatments such as Viagra, Cialis and Levitra, the St. Louis Post-Dispatch reports. Ma ny plans covered the treatments this year. [click link for full article] (Source: Erectile Dysfunction / Premature Ejaculation News From Medical News Today)

Most Medicare Prescription Drug Plans Will Drop Coverage For Erectile Dysfunction Medications In 2007

Sunday, May 30th, 2010

Most Medicare prescription drug plans in 2007 will not cover erectile dysfunction treatments such as Viagra, Cialis and Levitr a, the St. Louis Post-Dispatch reports. Many plans covered the treatments this year. According to the Post-Dispatch, “[m]any beneficiaries are learning of the change this week as they receive materials explaining next year’s benefits. [click link for full article] (Source: Health News from Medical News Today)

Vivus’s Qnexa Will Become Decision Resources’ Clinical Gold Standard In 2013 For The Treatment Of Obesity

Saturday, May 29th, 2010

Decision Resources, one of the world’s leading research and advisory firms for pharmaceutical and healthcare issues, finds that, for the treatment of obesity, Vivus’s Qnexa (the phentermine/topiramate combination) will earn Decision Resources’ propriet ary clinical gold standard in 2013 and through 2018 following its anticipated U.S. approval for the disease in 2011. Qnexa has competitive advantages in efficacy — it provides nearly double the (more…)

Vivus’s Qnexa Will Become Decision Resources’ Clinical Gold Standard In 2013 For The Treatment Of Obesity

Friday, May 28th, 2010

Decision Resources, one of the world’s leading research and advisory firms for pharmaceutical and healthcare issues, finds that, for the treatment of obesity, Vivus’s Qnexa (the phentermine/topiramate combination) will earn Decision Resources’ proprietary clinical gold standard in 2013 and through 2018 following its anticipated U.S. approval for the dis ease in 2011… (Source: Obesity / Weight Loss / Fitness News From Medical News Today)

Objecting Claimant Will Get New Audit, Judge Rules

Thursday, May 20th, 2010

PHILADELPHIA – The judge supervising the American Home Products National Settlement has resolved conflict over a trust auditor’s lapse in board certification for cardiovascular disease by ordering a new audit for the unsuccessful Matrix claimant who objected and allowing to stand the audits of 65 claimants who did not object (In Re: Diet Drugs [Phentermine/Fenfluramine/Dexfenfluramine] Products Liability Litigation, MDL Docket No. 1203, Sheila (more…)

Most Medicare Prescription Drug Plans will Drop Coverage for Erectile Dysfunction Medications

Friday, March 19th, 2010

UroToday.com(Press Release) – Most Medicare prescription drug plans in 2007 will not cover erectile dysfunction treatments such as Viagra, Cialis… (Source: UroToday)

MedWorm Message: Get the very latest Swine Flu news via the MedWorm Swine Flu RSS news feed – updated ho urly from thousands of authoritative health and news sources.

Flibanserin Drug: Will ‘Female Viagra’ Boost Sex Drive?

Thursday, March 4th, 2010

Drug companies have long sought to develop the “female Viagra,” but it’s hard to find a cure when you don’t know exactly what you’re t reating (Source: TIME.com: Top Science and Health Stories)

MedWorm Message: Get the very latest Swine Flu news via the MedWorm Swine Flu RSS news feed – updated hourly from thousands of authoritative health and news sources.

Vivus’s Qnexa Will Become Decision Resources’ Clinical Gold Standard In 2013 For The Treatment Of Obesity

Wednesday, March 3rd, 2010

Decision Resources, one of the world’s leading research and advisory firms for pharmaceutical and healthcare issues, finds that, for the treatment of obesity, Vivus’s Qnexa (the phentermine/topiramate combination) will ea rn Decision Resources’ proprietary clinical gold standard in 2013 and through 2018 following its anticipated U.S. approval for the disease in 2011. Qnexa has competitive advantages in efficacy — it provides nearly double the (more…)

Vivus’s Qnexa Will Become Decision Resources’ Clinical Gold Standard In 2013 For The Treatment Of Obesity

Wednesday, March 3rd, 2010

Decision Resources, one of the world’s leading research and advisory firms for pharmaceutical and healthcare issues, finds that, for the treatment of obesity, Vivus’s Qnexa (the phentermine/topiramate combination) will earn Decision Resources’ proprietary clinical gold standard in 2013 and throu gh 2018 following its anticipated U.S. approval for the disease in 2011… (Source: Obesity / Weight Loss / Fitness News From Medical News Today)

Erectile Dysfunction Drugs Will Warn Users About Sudden Hearing Loss

Wednesday, March 3rd, 2010

ROCKVILLE, Md. – Labels for Viagra, Levitra, Cialis and Revatio will warn users of reports of sudden hearing loss, the U.S. Food and Drug Administration announced Oct. 18.
Full story on lexis.com (Sou rce: LexisNexis® Mealey’s™ Emerging Drugs & Devices Legal News)

MedWorm Message: Get the very latest Swine Flu news via the MedWorm Swine Flu RSS news feed – updated hourly from thousands of authoritative health and news (more…)

Page 1 of 212